Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. https://doi.org/10.1126/science.3798106
2. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R (2010) Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest 28(9):963–968
3. Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, Sánchez-Lorenzo L, Palacio-Vázquez I (2016) Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome It. Clin Med Insights Oncol. 10(Suppl 1):21–30
4. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972–2977
5. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J et al (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64(11):3958–3965
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献